This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. Browse full report @ http://bit.ly/1HiLlHF
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Category : Healthcare Aarkstore - Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023
Summary Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. Taiho Pharmaceuticals Lonsurf (TAS-102) is an oral nucleoside antitumor drug which launched in 2014 for the treatment of chemotherapy-refractive metastatic CRC in Japan. In May 2014, Taiho Pharmaceutical announced that the Phase III RECOURSE trial met its primary outcome of OS and that the company is preparing for regulatory submission in the US and Europe. Browse Complete Report – http://www.aarkstore.com/healthcare/87979/lonsurf-colorectal-cancer-forecast-and-market-analysis-to-2023
Scope - Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Lonsurf including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Lonsurf for the top eight countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.
Reasons to buy • Understand and capitalize by identifying products that are most likely to ensure a robust return • Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Lonsurf performance
Table of Content 1.1 List of Tables 7 2 Introduction 8 2.1 Catalyst 8 2.2 Related Reports 9 2.3 Upcoming Related Reports 10 3 Disease Overview 11 3.1 Etiology and Pathophysiology 11 3.1.1 Etiology 11 3.1.2 Pathophysiology 13 3.2 Clinical Staging 14 3.3 Symptoms 15
List of Tables Table 1: TNM and Staging Classification System for CRC 15 Table 2: Symptoms of Colorectal Cancer 16 Table 3: Treatment Guidelines for CRC 21 Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 22 Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 23 Table 6: Leading Treatments for CRC, 2014 32 Table 7: Product Profile - Lonsurf 35 Table 8: Lonsurf SWOT Analysis, 2014 37 Table 9: Global Sales Forecasts ($m) for Lonsurf (TAS-102), 2013-2023 38 Table 10: Average Body Weight and Surface Area Across the 8MM 49 Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 53
Related reports: • OpportunityAnalyzer: Gout - Opportunity Analysis and Forecast to 2018 • Linzess (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023 • North American Nerve Repair & Regeneration Market by Type (Neurostimulation, Nerve Conduits, Nerve Protectors, Nerve Wraps, Nerve Connectors), by Procedure (Direct Nerve Repair, Nerve Grafting, Neuromodulation Surgery, Stem Cell Therapy) -Forecast to 2019 • Asian Stationary Cycle Market by Product (Recumbent Stationary Cycle, Upright Stationary Cycle), by Pricing of Equipment ( Premium Equipment, Budget Equipment), by End User (Vertical Markets, Health Clubs, Home Fitness) - Forecasts to 2019 • Oncology Information System Market by Software (Patient Information System & TPS), & Professional Service), Application (Medical, Radiation, & Surgical Oncology), End User (Hospital, Government Institution, & Research Center) - Global Forecasts to 2019
Lonsurf (Colorectal Cancer) Published: Nov 2014 | 57 Pages Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. Price
Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at firstname.lastname@example.org Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news